Plachouri K-M, Georgiou S
Dermatology Department, University General Hospital of Patras, Greece.
Drugs Today (Barc). 2020 Feb;56(2):151-163. doi: 10.1358/dot.2020.56.2.3100503.
Janus kinase (JAK) inhibitors are novel small molecules with a mechanism of action in multiple signaling pathways that allows their application in a broad spectrum of autoimmune and autoinflammatory diseases. As far as the field of dermatology is concerned, chronic plaque psoriasis is currently one of the most studied indications regarding the potential use of JAK inhibitors. The purpose of this review is to provide a summarized overview of the existing information on the efficacy and safety of JAK inhibitors in plaque psoriasis, with a focus on tofacitinib, ruxolitinib, baricitinib, peficitinib and filgotinib. Although the published data on the therapeutic benefit of these agents in the therapy of this chronic condition are promising, further prospective studies and real-life data are necessary in order to sufficiently evaluate their role as an adequate treatment option for psoriatic patients.
Janus激酶（JAK）抑制剂是一类新型小分子药物，其作用机制涉及多条信号通路，使其可应用于多种自身免疫性和自身炎症性疾病。就皮肤病学领域而言，慢性斑块状银屑病是目前关于JAK抑制剂潜在用途研究最多的适应症之一。本综述的目的是总结现有关于JAK抑制剂治疗斑块状银屑病的疗效和安全性的信息，重点关注托法替布、鲁索替尼、巴瑞替尼、培非替尼和非戈替尼。尽管已发表的关于这些药物治疗这种慢性疾病的疗效数据很有前景，但仍需要进一步的前瞻性研究和实际应用数据，以便充分评估它们作为银屑病患者合适治疗选择的作用。
